Clinical Trial

DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays

Study acronym: DISARM CSB
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Ovarian cancer is often diagnosed at a later stage because early symptoms can be mild or non-specific. Earlier detection of ovarian cancer could improve treatment options and outcomes. Recent research has focused on the development of blood-based tests, sometimes referred to as liquid biopsy tests, which aim to look for changes in the blood that could be linked to cancer. These tests are still under investigation and are not part of routine clinical care. The purpose of this study is to evaluate several blood-based ovarian cancer tests. This will be done by comparing test results from people who have ovarian cancer with results from people who do not have cancer. The study will also collect information from standard blood tests and genetic analyses to better understand how these results relate to ovarian cancer. This study is for research purposes only. The blood-based tests being evaluated are investigational and are not used to make medical decisions or diagnoses for women taking part in the study.
Trial Details
NCT Number NCT07693894
Lead Sponsor National and Kapodistrian University of Athens
Collaborators: European Commission
Conditions Ovarian Cancer
Enrollment 2,080 participants
Start Date 2026-07
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-09